Indications
Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.
Composition
- Active substance
- sodium thiosulfate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Pedmarqsi
- Active substance
- sodium thiosulfate
- Therapeutic area
- Ear Diseases, Ototoxicity
- Marketing authorisation holder
- Norgine B.V.
- Status
- Authorised
- EU authorisation
- 26 May 2023
- EMA product number
- EMEA/H/C/005130
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- No
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No